We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Flow Diverting Stent Helps Contain Cerebrovascular Defects

By HospiMedica International staff writers
Posted on 24 Jul 2018
Image: The Surpass Streamline Flow Diverter in proximity to an aneurysm (Photo courtesy of Stryker).
Image: The Surpass Streamline Flow Diverter in proximity to an aneurysm (Photo courtesy of Stryker).
An innovative flow diverter embolization device protects susceptible patients from large and giant brain unruptured aneurysms.

The Stryker (Kalamazoo, MI, USA) Surpass Streamline Flow Diverter is a cobalt chromium braided stent that directs blood flow within an intracranial artery away from a weakened blood vessel sac or aneurysm. The high-mesh density of the braid is achieved by increasing the number of braid wires in concert with device diameter; while the 2 mm device has 48 braided wires, the 3 and 4 mm devices have 72 braided wires, and the 5 mm device has 96 wires, providing a more uniform pore density over different sizes.

Filament sizes change from 25 to 36 mm, depending on the device diameter. The increase in wires maintains consistent density across a range of vessel sizes, thereby facilitating reliable and consistent occlusion of the aneurysm over time, and helping to reduce the risk of a future rupture. In addition, the braid angle is designed to prevent unwanted changes in mesh density around curves and to minimize foreshortening. The Surpass Streamline Flow Diverter is loaded within a 3.7-Fr distal catheter with a pusher catheter and accepts a 0.014-inch micro-guidewire.

Surpass Streamline can be positioned using the Surpass delivery system, designed for consistent deployment; the Halo delivery system, which provides atraumatic access to distal vasculature using an intermediate catheter, improving stent fit and climbing performance; or the Streamline delivery system, which allows it to be repositioned distally or proximally, and to be redeployed until precise placement and enhanced vessel apposition are achieved.

“Surpass Streamline is the first flow diverter indicated for large and giant posterior communicating artery aneurysms; these unruptured aneurysms are more challenging, due to their location and surrounding anatomy,” said professor of radiology and neurological surgery Philip Meyers, MD, of New York Presbyterian/Columbia University Medical Center (NY, USA). “The stent is designed to reliably open and provide consistent mesh density across the neck of the aneurysm to aid in aneurysm occlusion while maintaining perforator artery patency.”

While originally indicated for wide-necked or fusiform aneurysms from the petrous segment to the clinoid segment of the internal carotid artery (ICA), flow diversion today is being more broadly applied to small aneurysms, anterior cerebral artery aneurysms, recurrent aneurysms, and other endoluminal and intra-saccular defects.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Absorbable Monofilament Mesh
Phasix Mesh
New
Portable Ventilator
Oxivent Oxi4Plus

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more